Dr. Trevor Hallam has more than 25 years of experience in pharmaceutical discovery and development. He joined Sutro Biopharma as CSO in late 2010. Since then Dr. Hallam has shaped Sutro's biochemical synthesis technology to generate a disruptive discovery and manufacturing platform for novel best-in-class bispecific and antibody-drug conjugate protein therapeutics. Prior to Sutro, Dr. Hallam has held several senior R&D positions in the US and Europe, most recently Vice President Biologics, Vice President U.S. Medical Affairs, and Vice President, Research and Pre-clinical Development at AstraZeneca. He began his pharmaceutical career in the UK working for Smith Kline & French followed by senior management positions at Glaxo and Roche. Dr. Hallam conducted his post-doctoral training in the laboratory of Timothy Rink MD DSc at the Physiological Laboratory, University of Cambridge after receiving his Ph.D. in Biochemistry from King's College, University of London.